Skip to content

Preemptive Versus Preventive Antiemetic Treatment

Effectiveness of Preemptive Versus Preventive Antiemetic Treatment in Patients Undergoing Laparoscopic Cholecystectomy. A Randomized Double Blind Trial.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03023306
Enrollment
115
Registered
2017-01-18
Start date
2018-11-30
Completion date
2020-11-30
Last updated
2018-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Nausea and Vomiting

Brief summary

Patients aged between 20 and 70 years, ASA physical status I-III, and scheduled for laparoscopic cholecystectomy under general anaesthesia will be enrolled in the study. Patients will be randomized to the preemptive group to receive an antiemetic regime 1h before the start of surgery or to the intraoperative group to receive the same antiemetic drugs in the same doses intraoperatively, 30 min before the end of surgery. In the operating room standard monitoring and a standardized anesthetic technique will be implemented in all patients. Nausea, vomiting, retching and PONV (cumulative) will be recorded at PACU, at 4h, 8h and 24h postoperatively. Pain scores assessed by NRS (numerical rating scale) will be recorded at the same time points. Also, when patients received fluids and solid food by mouth will be recorded.

Interventions

OTHERAntiemetics perioperatively

Preemptive group ondansetron 4 mg will be administered 1h before surgery Intraoperative group Ondansetron 4 mg will be administered intraoperatively

Sponsors

University of Athens
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* ASA physical status I-III patients * Surgical procedure: scheduled for laparoscopic cholecystectomy * Type of anesthesia: general

Exclusion criteria

* Antihistamines the last three days * Antiemetic drugs the last three days * Hiatus hernia * reflux * Gastrointestinal disease * Pregnancy * BMI \> 35 * parkinson * known allergy to the drugs of the protocol * epilepsy

Design outcomes

Primary

MeasureTime frameDescription
PONV (postoperative nausea vomiting combined)24 hoursIncidence of combined nausea and vomiting postoperatively

Secondary

MeasureTime frameDescription
postoperative nausea frequency and intensity24 hoursnumerical rating scale of nausea intensity (0-10)
postoperative vomiting frequency24 hoursnumber of vomits
postoperative pain24 hoursnumerical rating scale of pain intensity (0-10)
retching24 hoursif retching exists
PONV (postoperative nausea vomiting combined)24 hoursfrequency and intensity of nausea and vomiting

Countries

Greece

Contacts

Primary ContactArgyro Fassoulaki, MD PhD DEAA
afassou1@otenet.gr306936701333
Backup ContactChryssoula Staikou, MD, PhD, DESA
c_staikou@yahoo.gr00306932352742

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026